

2017-05-22

Boule Diagnostics strengthens the management team

Boule Diagnostics is taking the next step in the development and strengthening of the management. As of June 1, Debbie Herrera and Fredrik Ekdahl will be joining the group management team. Debbie Herrera has been employed by Boule in Florida since early 2017, and she brings significant experience in Quality and Regulatory affairs from her tenure at Beckman Coulter and other companies in the industry. Fredrik Ekdahl has been working for Boule in Sweden since 2012, when he joined from Biotage. Thomas Olsson who has been responsible for Quality and Regulatory Affairs up until now, will leave the group management team as of June 1, but will continue to work part time for Boule.

After the changes the group management team will include:

Fredrik Dalborg	Chief Executive Officer and Group President
Fredrik Alpsten	SVP and Chief Financial Officer
Claes Blanche	SVP Global Sales
Fredrik Ekdahl	SVP R&D Systems
Michael Elliott	SVP R&D Consumables and OEM
Debbie Herrera	SVP Quality and Regulatory
Hans Johansson	SVP Production

"With this change we will be strengthening the R&D focus in the group management team, with Fredrik Ekdahl reporting directly to me. With Debbie Herrera joining the group management team we will be adding significant international experience as well as experience in collaboration with the US FDA. This will strengthen our ability to continue to improve current products and develop and launch new ones. I also want to thank Thomas Olsson for many years of hard work and valuable contributions at Boule and in the group management team, and I am grateful that for a period of time we will be able to continue to benefit from his expertise and experience", says Fredrik Dalborg, CEO and Group President, Boule Diagnostics.

For further information, please contact:

Fredrik Dalborg, CEO, Boule Diagnostics AB, tel +46 705-58 51 05

About Boule Diagnostics AB (publ)

Boule Diagnostics AB is a fast growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule's own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

This information was submitted for publication, through the agency of the contact person set out above, at 08:45 May 22, 2017.